Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN0025 with Chemoradiotherapy in Esophageal Cancer
NCT05191667Phase 1Suspended
- Sponsor
- Adlai Nortye
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palupiprant in esophageal cancer and esophagogastric junction cancer, sponsored by Adlai Nortye. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Jan 2022; status: suspended.
02
Drugs
palupiprant
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NCT05191667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191667.